|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2005-5-16
|
|
pubmed:abstractText |
The CHARM program was designed as 3 separate randomized trials comparing candesartan with placebo in patients with chronic heart failure (CHF) who (1) were intolerant to angiotensin-converting enzyme inhibitor and had left ventricular ejection fraction (LVEF) < or =0.40; (2) were on angiotensin-converting enzyme inhibitor and had LVEF < or =0.40; or (3) had LVEF >0.40. CHARM provides an interesting example of the challenges faced by a Data and Safety Monitoring Committee (DSMC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1097-6744
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
149
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
939-43
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15894981-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:15894981-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:15894981-Benzimidazoles,
pubmed-meshheading:15894981-Clinical Trials Data Monitoring Committees,
pubmed-meshheading:15894981-Double-Blind Method,
pubmed-meshheading:15894981-Drug Therapy, Combination,
pubmed-meshheading:15894981-Heart Failure,
pubmed-meshheading:15894981-Humans,
pubmed-meshheading:15894981-Morbidity,
pubmed-meshheading:15894981-Randomized Controlled Trials as Topic,
pubmed-meshheading:15894981-Stroke Volume,
pubmed-meshheading:15894981-Tetrazoles,
pubmed-meshheading:15894981-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
|
|
pubmed:affiliation |
Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom.
|
|
pubmed:publicationType |
Journal Article
|
